TY - JOUR AU - Amornrat Temtanakitpaisan AU - Pilaiwan Kleebkaow AU - Apiwat Aue-aungkul PY - 2018/11/09 Y2 - 2024/03/28 TI - Epithelial Borderline Ovarian Tumor: Clinicopathological Features, Outcome and Prognostic Factors JF - Asian Pacific Journal of Cancer Care JA - apjcc VL - 3 IS - 4 SE - Original Research DO - 10.31557/apjcc.2018.3.4.75 UR - http://waocp.com/journal/index.php/apjcc/article/view/26 AB - Objective: To evaluate clinic-pathological characteristics, treatment outcomes, factors affecting survival in patients with borderline ovarian tumors (BOTs).Methods and Objective: Medical records of patients with BOTs who had been treated at Srinagarind Hospital from 2001 to 2016 were reviewed. Abstracted data included baseline characteristics, clinic-pathologic features, disease-free survival (DFS), and overall survival (OS). Results: Fifty-two patients with BOTs were included in the study.The mean age+ SD was 41.15+ 15.34 years. Most patients were premenopausal and the most common presenting symptom was adnexal mass. Most patients were in the early stage (90.4%). Thirty-two patients underwent radical surgery (61.5%). Twenty-one patients (40.3%) underwent lymphadenectomy. An appendectomy was performed in 19 (36.5 %) cases. The median follow-up period was 67.5 months (range, 7 to 180 months). The 5-year and 10-year overall survival rates for all stages were 90% and 85%, respectively. The 5-year and 10-year disease-free survival rates for all stages was 87% and 87%, respectively. Seven (13.5 %) patients had the recurrence. Absent residual disease (HR = 0.33; 95 %CI 0.11 – 0.96) and receiving postoperative adjuvant chemotherapy (HR = 0.22; 95 %CI 0.08 – 0.65) were associated factors for DFS. Conclusion: The majority of patients with BOTs presented at the young age and early stage. Residual lesion and adjuvant chemotherapy are significant factors predicting DFS. ER -